Read More

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hemato

SNTI

Read More

Dow Rises 50 Points; Fed’s Preferred Inflation Gauge Cools In November

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose 0.30% to 15,008.08. The S&P 500 also rose, gaining, 0.31% to 4,761.25.

ALVR

Read More

Why Is Penny Stock Cell Therapy Focused AlloVir Stock Plummeting Today?

AlloVir Inc (NASDAQ: ALVR) provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-

ALVR

Read More

Small-Cap Cancer Focused Theseus Pharmaceuticals Goes Private For Over $3.90/Share In Cash

Theseus Pharmaceuticals Inc (NASDAQ: THRX) on Friday, has entered into a definitive merger agreement whereby Concentra Biosciences LLC will acquire Theseus for a price per share of between $3.90 and $4.05 in cash, consisting of a base cash price of $3.90 per share and an addi

THRX